Clinical trials: Service Utilization
- Condition Service Utilization
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Organ Preservation
A Central Preservation and Assessment Service to Optimize Donor Kidney Allocation
This is a study to collect information to assess if transporting hard-to-place (HTP) donor kidneys to a central preservation and assessment facility with dedicated organ assessment capabilities increases allocation success to…
- Trial name
- OPTIMAL (NCT06263023)
- Testing
- Sub-Normothermic Machine Preservation and Assessment
- Where
- 8 sites in United States
- Volunteers
- 80 people
- Sponsor
- 34 Lives, PBC
Sport Medicine
ATI Evidence-based Guide Investigating Medical and Preventative Services
To use existing standard-of-care documentation in a sports medicine electronic medical record (EMR) to evaluate patient characteristics, interventions delivered, utilization management, and clinical outcomes in routine sports…
- Trial name
- NCT04050319
- Testing
- Screening and diagnosis if injured
- Where
- United States
- Volunteers
- 550,000 people, healthy volunteers welcome
- Sponsor
- ATI Holdings, LLC
Prostate Cancer
Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body
Study to gather information about the optimal placement of Ra-223 in the order of different treatments in terms of the effect on patients and in terms of the use of healthcare services for the treatment of Canadian patients with…
- Trial name
- REACTIVATE (NCT04281147)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- Canada
- Volunteers
- 4,301 people
- Sponsor
- Bayer
Epilepsy
Naturalistic Study to Evaluate the Utilization of Care Services Associated to the Diagnostic Process of Any Kind of Epilepsy
Naturalistic, multicentre, epidemiological study to evaluate the care services used during the process of diagnosis of any kind of epilepsy. Data about services since first seizure until confirmed diagnosis will be examined.
- Trial name
- NCT00522522
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- UCB Pharma